Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Sotio Biotech Inc.
PMV Pharmaceuticals, Inc
NeoImmuneTech
Neonc Technologies, Inc.
ImmunityBio, Inc.
VM Oncology, LLC
Amgen
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Blanco, Dr Antonio Calles MD
OncoC4, Inc.
Inspirna, Inc.
Seagen Inc.
Carisma Therapeutics Inc
Sellas Life Sciences Group
Salubris Biotherapeutics Inc
Evopoint Biosciences Inc.
University of Florida
European Organisation for Research and Treatment of Cancer - EORTC
Fate Therapeutics
Xencor, Inc.
Alliance Foundation Trials, LLC.
Merck Sharp & Dohme LLC
Gossamer Bio Inc.
NYU Langone Health
Aeglea Biotherapeutics
Incyte Corporation
Merck Sharp & Dohme LLC
MultiVir, Inc.
Incyte Corporation
Seoul National University Hospital
Western Regional Medical Center
Case Comprehensive Cancer Center